UK Readies Medtech And Pharma Sectors For Regulatory Life Outside The EU

Work has started on UK-only regulations for the medtech and medicines sectors, to ensure that the regulatory framework not only functions but can also react swiftly to needs after the UK leaves the EU. This article is part two of two.

New_Regulations_Notebook

In the case where post-2020 alignment with EU medtech legislation and regulations does not happen during the UK-EU free trade agreement negotiations this year ̶ where mutual recognition is roundly rejected by the EU, and UK Prime Minister Boris Johnson acts on his promise to withdraw the UK from the EU on a no-deal basis ̶ the medtech and medicines sectors will be ready and covered, in regulatory terms.

That is the intention, at least, of efforts now underway to draft a Medicines and Medical Devices (MMD) bill. Initial...

More from Regulation

More from Policy & Regulation